AKTing on XPO1 inhibition in AML
Inhibition of XPO1-mediated nuclear export by selinexor represents a promising therapeutic strategy in acute myeloid leukemia. Because XPO1 is not specific for tumor-suppressive proteins, selinexor may also activate pro-oncogenic processes. A study now shows that inhibition of selinexor-induced, pur...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
26 July 2022
|
| In: |
Nature cancer
Year: 2022, Jahrgang: 3, Heft: 7, Pages: 787-789 |
| ISSN: | 2662-1347 |
| DOI: | 10.1038/s43018-022-00395-w |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s43018-022-00395-w Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s43018-022-00395-w 
|
| Verfasserangaben: | Stefanie Göllner and Carsten Müller-Tidow |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1814746579 | ||
| 003 | DE-627 | ||
| 005 | 20230118152920.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220819s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s43018-022-00395-w |2 doi | |
| 035 | |a (DE-627)1814746579 | ||
| 035 | |a (DE-599)KXP1814746579 | ||
| 035 | |a (OCoLC)1361706427 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Göllner, Stefanie |d 1979- |e VerfasserIn |0 (DE-588)133882764 |0 (DE-627)557870151 |0 (DE-576)300169191 |4 aut | |
| 245 | 1 | 0 | |a AKTing on XPO1 inhibition in AML |c Stefanie Göllner and Carsten Müller-Tidow |
| 246 | 3 | 0 | |a one |
| 264 | 1 | |c 26 July 2022 | |
| 300 | |a 3 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 19.08.2022 | ||
| 520 | |a Inhibition of XPO1-mediated nuclear export by selinexor represents a promising therapeutic strategy in acute myeloid leukemia. Because XPO1 is not specific for tumor-suppressive proteins, selinexor may also activate pro-oncogenic processes. A study now shows that inhibition of selinexor-induced, purinergic receptor-mediated AKT activation potentiates its anti-leukemic activity. | ||
| 650 | 4 | |a Acute myeloid leukaemia | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Cell signalling | |
| 650 | 4 | |a High-throughput screening | |
| 650 | 4 | |a Targeted therapies | |
| 700 | 1 | |a Müller-Tidow, Carsten |d 1968- |e VerfasserIn |0 (DE-588)1015101798 |0 (DE-627)705330230 |0 (DE-576)351197893 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature cancer |d London : Nature Research, 2020 |g 3(2022), 7, Seite 787-789 |h Online-Ressource |w (DE-627)1687330697 |w (DE-600)3005299-3 |x 2662-1347 |7 nnas |a AKTing on XPO1 inhibition in AML |
| 773 | 1 | 8 | |g volume:3 |g year:2022 |g number:7 |g pages:787-789 |g extent:3 |a AKTing on XPO1 inhibition in AML |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s43018-022-00395-w |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/s43018-022-00395-w |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220819 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 1015101798 |a Müller-Tidow, Carsten |m 1015101798:Müller-Tidow, Carsten |d 910000 |d 910100 |e 910000PM1015101798 |e 910100PM1015101798 |k 0/910000/ |k 1/910000/910100/ |p 2 |y j | ||
| 998 | |g 133882764 |a Göllner, Stefanie |m 133882764:Göllner, Stefanie |d 910000 |d 910100 |e 910000PG133882764 |e 910100PG133882764 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1814746579 |e 4181046486 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"doi":["10.1038/s43018-022-00395-w"],"eki":["1814746579"]},"name":{"displayForm":["Stefanie Göllner and Carsten Müller-Tidow"]},"physDesc":[{"extent":"3 S."}],"recId":"1814746579","note":["Gesehen am 19.08.2022"],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"AKTing on XPO1 inhibition in AML","title_sort":"AKTing on XPO1 inhibition in AML"}],"person":[{"display":"Göllner, Stefanie","given":"Stefanie","role":"aut","family":"Göllner"},{"given":"Carsten","role":"aut","family":"Müller-Tidow","display":"Müller-Tidow, Carsten"}],"relHost":[{"disp":"AKTing on XPO1 inhibition in AMLNature cancer","physDesc":[{"extent":"Online-Ressource"}],"recId":"1687330697","note":["Gesehen am 14.01.20"],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"title":[{"title":"Nature cancer","title_sort":"Nature cancer"}],"part":{"text":"3(2022), 7, Seite 787-789","extent":"3","issue":"7","pages":"787-789","volume":"3","year":"2022"},"id":{"zdb":["3005299-3"],"issn":["2662-1347"],"eki":["1687330697"]},"pubHistory":["Volume 1, Issue 1, (January 2020)-"],"origin":[{"publisher":"Nature Research","dateIssuedDisp":"2020-","dateIssuedKey":"2020","publisherPlace":"London"}]}],"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"26 July 2022"}]} | ||
| SRT | |a GOELLNERSTAKTINGONXP2620 | ||